pTau-181 CLIA Kit
Alzheimer's Disease
DevelopmentActive
Key Facts
About Diazyme Laboratories
Diazyme Laboratories, founded in 1998 and headquartered in San Diego, is a privately-held diagnostics company with a mature commercial-stage business. It has built a robust portfolio of clinical chemistry and immunoassay reagents, with a significant new strategic focus on developing blood-based biomarker tests for neurodegenerative diseases like Alzheimer's. The company operates a vertically integrated model from R&D to global distribution, leveraging its core expertise in enzymology and immunoturbidimetric/chemiluminescence assay formats to serve the clinical laboratory market.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| ALZN002 | Alzamend Neuro | Preclinical |
| P021 | Phanes Biotech | Preclinical |
| PB43D | Phanes Biotech | Preclinical |
| UB-311 | Vaxxinity | Phase 2 |
| Lecanemab | BioArctic | Launched |
| BAN2401 | BioArctic | Preclinical |
| Undisclosed Programs | Johnson and Johnson Innovative Medicine | Pipeline |
| MK-6240 (florquinitau) | Lantheus Medical Imaging | Regulatory Filing |
| NAV-4694 (flutafuranol) | Lantheus Medical Imaging | Phase 3 |
| LNTH-2620/PI-2620 | Lantheus Medical Imaging | Phase 3 |
| itMSCs | Stemedica Cell Technologies | Clinical Development |
| PMN310 | ProMIS Neurosciences | Phase 1b |